Dror Bashan bought $101k of PLX
PRESIDENT AND CEO at Protalix BioTherapeutics, Inc.. 56,000 shares at an average of $1.81, traded Dec 19, 2025, filed Dec 23, 2025.
Score components
- +25RoleCEO
- +10Trade size$101k at market
- +6Relative to holdingsHoldings up 42%
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +19.4%, 3m +18.3%, 6m +24.0%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001781450-25-000005, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 19, 2025 | POpen-market purchase Common Stock | +56,000 | $1.81 | $101k | 188,516 | Dec 23, 2025 |
Related signals
Other insiders at Protalix BioTherapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 35Weak | PLXsell Protalix BioTherapeutics, Inc. | Amos Bar-Shalev director | $314 168 shares | -100% | |
| 37Weak | PLXbuy Protalix BioTherapeutics, Inc. | Aharon Schwartz director | $206k 129,000 shares | +74% | |
| 52Moderate | PLXbuy Protalix BioTherapeutics, Inc. | Dror Bashan PRESIDENT AND CEO | $90k 64,516 shares | +95% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.